When an offer needs a pause
An offer can wait for better answers.
If an offer leaves a question unanswered, bring it back to the exact product, the pharmacy making it, and the person handling your assessment.
Research wording does not explain a care offer
In letters issued during 2026, FDA (the US Food and Drug Administration) alleged that research-labelled peptide products were unapproved drugs when the surrounding claims showed intended human use.
As of September 26, 2026, these letters set out FDA’s allegations about particular firms. They were not court findings.
Ask why a research label appears in something being proposed as your care. It is a question that needs an answer before a price comparison.
Read note ALook past approval-sounding words
As of September 26, 2026, registration and a government drug-code listing still did not confer FDA approval.
For GHK-Cu, a drug code identifies a listing, not an approved product.
Read note B| The offer points to | Ask instead |
|---|---|
| Registration | What exact product approval are you claiming? |
| A substance or drug code | Where is the approval for the finished product? |
| A personalised preparation | What need does this preparation address for me? |
| A treatment menu | Who will assess whether this fits my situation? |
Ask for the pharmacy’s own name
FDA notes that someone receiving a pharmacy-made medicine through an online service may not know which pharmacy or facility actually made it.
Request that name before trying to check a record. If the answer is unclear, write down what is missing and return to the licence desk.
Use the licence and pharmacy records